Welcome to Curasight
Curasight is a pioneer in the field of exploiting a novel PET imaging target - the urokinase-type plasminogen activator receptor (uPAR) - for improved breast cancer diagnose.
To develop a first-in-class uPAR PET ligand for improved cancer diagnose.
Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Department of Nuclear Medicine, Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications.
Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.
Our vision is to improve the quality of lives of cancer patients by creating innovative PET imaging ligands that address unmet clinical needs in cancer.
30. Oct. 2016
Our phase I study just published online in Journal of Nuclear Medicine
15. Sep. 2016
Curasight to present at BioPharm-America in Boston.
See interview with our CSO, Prof. Andreas Kjaer talking about Curasight's technology at BioPharm-America